Login / Signup
Although current guidelines strongly recommend that dual antiplatelet therapy be administered early in treating patients with non-ST-segment-elevation acute myocardial infarction (NSTEMI), it is unclear whether…
TRILOGY At ESC: No Advantage For Prasugrel Over Clopidogrel In Medical ACS Patients
The newer antiplatelet agent prasugrel was no better than the old standby clopidogrel for treating patients with acute coronary syndrome (ACS) who are not undergoing…
Ticagrelor Joins Clopidogrel And Prasugrel In Updated NSTEMI Guidelines
Ticagrelor (Brilinta, AstraZeneca) gains equal standing with prasugrel (Effient, Lilly) and clopdiogrel in the newly released focused update of the ACCF/AHA guidelines for unstable angina…
FDA Approves Generic Clopidogrels As Plavix Loses Patent Protection
For the second time in the past six months, a cardiology mainstay drug has lost patent protection and gone generic. Today the FDA announced that it…
Proof-of-Concept for Bedside Rapid Genotyping Test of CYP2C19
A new point-of-care test can rapidly identify people with a common genetic variant associated with impaired clopidogrel function. The authors claim that this is the first…